COYA
Coya Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.20
−1.18%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$4.28
From 52W high−42.93%
Volume106480.00
Market cap$98.52M
P/E (TTM)—
P/S (TTM)12.3x
Div yield—
Key dataOct 19, 2026
Open
$4.28
From 52W high
−42.93%
Volume
106480.00
Market cap
$98.52M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−2.5x
P/E (TTM)
—
RSI (14)
38.9
MomentumView details →
1D Return
−1.18%
YTD Return
−25.72%
SummaryUpdated Jun 1, 2026
Coya Therapeutics, Inc. (NASDAQ:COYA) is a clinical-stage biotechnology company founded in 2020 and headquartered in Houston, Texas. The company went public in December 2022 and focuses on developing innovative therapeutic treatments that harness the power of regulatory T cells (Tregs) to treat neurodegenerative, autoimmune, and metabolic diseases. Coya represents a relatively new entrant in the specialized field of immunotherapy, specifically targeting diseases like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia through novel approaches involving cellular therapy and biologics.
Similar companies
Latest newsMore news →
Coya Therapeutics announced plans to initiate an open-label extension of its Phase 2/3 ALSTARS trial evaluating COYA 302 for amyotrophic lateral sclerosis, in response to requests from trial investigators.6d agoCoya Therapeutics reported its financial results for the second quarter of 2026 and provided a corporate update.70d ago